PG — Investor Relations & Filings

Polaris Group is a biotechnology company dedicated to the development of novel anti-cancer therapies and the provision of Contract Development and Manufacturing Organization (CDMO) services. The company’s core research focuses on ADI-PEG 20 (pegargiminase), a biological agent that utilizes metabolic therapy to target arginine-dependent cancers. This candidate is currently in late-stage clinical development for multiple indications, including mesothelioma, soft tissue sarcoma, and hepatocellular carcinoma. Polaris Group maintains a vertically integrated business model, encompassing drug design, clinical trial management, and internal manufacturing capabilities. It operates cGMP-compliant facilities and has expanded its CDMO portfolio to include complex injectables and synthetic peptides. The company aims to deliver innovative treatment options by leveraging its proprietary technology and global clinical partnerships.